2315 fundamentals
BIOCYTOGEN PHARMACEUTICALS (BEIJING financial statements, including revenue, expenses, profit, and loss
The total revenue of 2315 for the last semiannual is 444.83 M HKD, and it's 5.56% higher compared to the previous semiannual. The net income of H1 24 is -54.91 M HKD.
0.00
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: HKD
TTM